Late effects of BMT in SCD
| . | Bernaudin et al1 . | Vermylen et al,2 Brachet et al6 . | Eggleston et al,5 Walters et al9 . | Socie et al,4 Ade et al10 . |
|---|---|---|---|---|
| Pulmonary function | Not reported | Bronchiolitis obliterans in 2 | Stable compared to baseline at least up to 3 years after BMT | Restrictive defects are frequent at 3-6 months; obstructive defects are seen in 20% of patients, usually associated with cGVHD |
| Growth curve | “No change in mean height” | Normal or improved except in 2 with cGVHD | Normal if BMT was done before or after puberty5 | 1 standard deviation score below mean height and weight in TBI based BMT; near normal mean height and weight in chemo-based BMT |
| Gonadal function | Male: age appropriate testosterone, LH and FSH levels. Female: primary amenorrhea in many; secondary amenorrhea in 7 | Male: normal sexual maturation; small testes in all, oligospermia in 1, azospermia in another. Female: ovarian failure in 7, recovery in 2 others | Male: not reported. Female: ovarian failure in 4, recovery in 2 others | Male: significant reduction in spermatogenesis despite normal testosterone level. Onset of puberty usually not affected. Younger age at transplantation may have lower testicular volume and function. Female: hypergonadotrophic hypogonadism is common. Younger age at transplantation has better chance of ovarian recovery. |
| Late malignancy | Not reported | Not reported | Not reported | PTLD (1% at 10 years), solid tumors (2% at 10 years); lymphoma (rare), leukemia (rare) |
| Neurocognitive testing | Not reported | Not reported | Not reported | 20% of patients reported problems with memory in the first year after BMT; 10% have cognitive impairment; possible lower IQ levels |
| . | Bernaudin et al1 . | Vermylen et al,2 Brachet et al6 . | Eggleston et al,5 Walters et al9 . | Socie et al,4 Ade et al10 . |
|---|---|---|---|---|
| Pulmonary function | Not reported | Bronchiolitis obliterans in 2 | Stable compared to baseline at least up to 3 years after BMT | Restrictive defects are frequent at 3-6 months; obstructive defects are seen in 20% of patients, usually associated with cGVHD |
| Growth curve | “No change in mean height” | Normal or improved except in 2 with cGVHD | Normal if BMT was done before or after puberty5 | 1 standard deviation score below mean height and weight in TBI based BMT; near normal mean height and weight in chemo-based BMT |
| Gonadal function | Male: age appropriate testosterone, LH and FSH levels. Female: primary amenorrhea in many; secondary amenorrhea in 7 | Male: normal sexual maturation; small testes in all, oligospermia in 1, azospermia in another. Female: ovarian failure in 7, recovery in 2 others | Male: not reported. Female: ovarian failure in 4, recovery in 2 others | Male: significant reduction in spermatogenesis despite normal testosterone level. Onset of puberty usually not affected. Younger age at transplantation may have lower testicular volume and function. Female: hypergonadotrophic hypogonadism is common. Younger age at transplantation has better chance of ovarian recovery. |
| Late malignancy | Not reported | Not reported | Not reported | PTLD (1% at 10 years), solid tumors (2% at 10 years); lymphoma (rare), leukemia (rare) |
| Neurocognitive testing | Not reported | Not reported | Not reported | 20% of patients reported problems with memory in the first year after BMT; 10% have cognitive impairment; possible lower IQ levels |